[1]
Zhuang Z, Liu X, Bao X, Pan B, Deng K, Yao Y, Lian W, Xing B, Zhu H, Lu L, Wang R, Feng M. Invasive ACTH-secreting pituitary macroadenoma in remission after transsphenoidal resection: A case report and literature review. Medicine. 2018 Nov:97(46):e13148. doi: 10.1097/MD.0000000000013148. Epub
[PubMed PMID: 30431585]
Level 3 (low-level) evidence
[2]
Huang IS, Wren J, Bennett NE, Brannigan RE. Clinical Consultation Guide on Imaging in Male Infertility and Sexual dysfunction. European urology focus. 2018 Apr:4(3):338-347. doi: 10.1016/j.euf.2018.09.018. Epub 2018 Oct 14
[PubMed PMID: 30327281]
[3]
Barake M, Klibanski A, Tritos NA. MANAGEMENT OF ENDOCRINE DISEASE: Impulse control disorders in patients with hyperpolactinemia treated with dopamine agonists: how much should we worry? European journal of endocrinology. 2018 Dec 1:179(6):R287-R296. doi: 10.1530/EJE-18-0667. Epub
[PubMed PMID: 30324793]
[4]
Melmed S. Pituitary-Tumor Endocrinopathies. The New England journal of medicine. 2020 Mar 5:382(10):937-950. doi: 10.1056/NEJMra1810772. Epub
[PubMed PMID: 32130815]
[6]
Lake MG, Krook LS, Cruz SV. Pituitary adenomas: an overview. American family physician. 2013 Sep 1:88(5):319-27
[PubMed PMID: 24010395]
Level 3 (low-level) evidence
[7]
Sharma AN, Tan M, Amsterdam EA, Singh GD. Acromegalic cardiomyopathy: Epidemiology, diagnosis, and management. Clinical cardiology. 2018 Mar:41(3):419-425. doi: 10.1002/clc.22867. Epub 2018 Mar 25
[PubMed PMID: 29574794]
[8]
Leonart LP, Borba HHL, Ferreira VL, Riveros BS, Pontarolo R. Cost-effectiveness of acromegaly treatments: a systematic review. Pituitary. 2018 Dec:21(6):642-652. doi: 10.1007/s11102-018-0908-0. Epub
[PubMed PMID: 30159696]
Level 1 (high-level) evidence
[9]
Petersenn S, Fleseriu M, Casanueva FF, Giustina A, Biermasz N, Biller BMK, Bronstein M, Chanson P, Fukuoka H, Gadelha M, Greenman Y, Gurnell M, Ho KKY, Honegger J, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Lodish M, Maiter D, Marcus HJ, McCormack A, Molitch M, Muir CA, Neggers S, Pereira AM, Pivonello R, Post K, Raverot G, Salvatori R, Samson SL, Shimon I, Spencer-Segal J, Vila G, Wass J, Melmed S. Diagnosis and management of prolactin-secreting pituitary adenomas: a Pituitary Society international Consensus Statement. Nature reviews. Endocrinology. 2023 Dec:19(12):722-740. doi: 10.1038/s41574-023-00886-5. Epub 2023 Sep 5
[PubMed PMID: 37670148]
Level 3 (low-level) evidence
[10]
Ioachimescu AG, Fleseriu M, Hoffman AR, Vaughan Iii TB, Katznelson L. Psychological effects of dopamine agonist treatment in patients with hyperprolactinemia and prolactin-secreting adenomas. European journal of endocrinology. 2019 Jan 1:180(1):31-40. doi: 10.1530/EJE-18-0682. Epub
[PubMed PMID: 30400048]
[11]
Fountas A, Chai ST, Kourkouti C, Karavitaki N. MECHANISMS OF ENDOCRINOLOGY: Endocrinology of opioids. European journal of endocrinology. 2018 Oct 1:179(4):R183-R196. doi: 10.1530/EJE-18-0270. Epub 2018 Oct 1
[PubMed PMID: 30299887]
[12]
Palejwala SK, Conger AR, Eisenberg AA, Cohan P, Griffiths CF, Barkhoudarian G, Kelly DF. Pregnancy-associated Cushing's disease? An exploratory retrospective study. Pituitary. 2018 Dec:21(6):584-592. doi: 10.1007/s11102-018-0910-6. Epub
[PubMed PMID: 30218242]
Level 2 (mid-level) evidence
[13]
Sharma ST, Nieman LK, Feelders RA. Cushing's syndrome: epidemiology and developments in disease management. Clinical epidemiology. 2015:7():281-93. doi: 10.2147/CLEP.S44336. Epub 2015 Apr 17
[PubMed PMID: 25945066]
[14]
Steffensen C, Bak AM, Rubeck KZ, Jørgensen JO. Epidemiology of Cushing's syndrome. Neuroendocrinology. 2010:92 Suppl 1():1-5. doi: 10.1159/000314297. Epub 2010 Sep 10
[PubMed PMID: 20829610]
[15]
Ónnestam L, Berinder K, Burman P, Dahlqvist P, Engström BE, Wahlberg J, Nyström HF. National incidence and prevalence of TSH-secreting pituitary adenomas in Sweden. The Journal of clinical endocrinology and metabolism. 2013 Feb:98(2):626-35. doi: 10.1210/jc.2012-3362. Epub 2013 Jan 7
[PubMed PMID: 23295463]
[16]
Ntali G, Capatina C, Grossman A, Karavitaki N. Clinical review: Functioning gonadotroph adenomas. The Journal of clinical endocrinology and metabolism. 2014 Dec:99(12):4423-33. doi: 10.1210/jc.2014-2362. Epub
[PubMed PMID: 25166722]
[17]
Tichomirowa MA, Daly AF, Beckers A. Familial pituitary adenomas. Journal of internal medicine. 2009 Jul:266(1):5-18. doi: 10.1111/j.1365-2796.2009.02109.x. Epub
[PubMed PMID: 19522822]
[18]
Wang L, Liang H, Deng C, Yu Q, Gong F, Feng F, You H, Liang Z, Chen B, Deng K, Ma J, Wang R, Yao Y, Zhu H. Functioning gonadotroph adenomas in premenopausal women: clinical and molecular characterization and review of the literature. Pituitary. 2022 Jun:25(3):454-467. doi: 10.1007/s11102-021-01205-9. Epub 2022 Feb 9
[PubMed PMID: 35138520]
[19]
Patel S, Pacione D, Fischer I, Maloku E, Agrawal N. FOLLICLE-STIMULATING HORMONE-PRODUCING PITUITARY ADENOMA: A CASE REPORT AND REVIEW OF THE LITERATURE. AACE clinical case reports. 2019 May-Jun:5(3):e175-e180. doi: 10.4158/ACCR-2018-0454. Epub 2019 Apr 25
[PubMed PMID: 31967028]
Level 3 (low-level) evidence
[20]
Giraldi E, Allen JW, Ioachimescu AG. Pituitary Incidentalomas: Best Practices and Looking Ahead. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2023 Jan:29(1):60-68. doi: 10.1016/j.eprac.2022.10.004. Epub 2022 Oct 18
[PubMed PMID: 36270609]
[21]
Giustina A, Barkhoudarian G, Beckers A, Ben-Shlomo A, Biermasz N, Biller B, Boguszewski C, Bolanowski M, Bollerslev J, Bonert V, Bronstein MD, Buchfelder M, Casanueva F, Chanson P, Clemmons D, Fleseriu M, Formenti AM, Freda P, Gadelha M, Geer E, Gurnell M, Heaney AP, Ho KKY, Ioachimescu AG, Lamberts S, Laws E, Losa M, Maffei P, Mamelak A, Mercado M, Molitch M, Mortini P, Pereira AM, Petersenn S, Post K, Puig-Domingo M, Salvatori R, Samson SL, Shimon I, Strasburger C, Swearingen B, Trainer P, Vance ML, Wass J, Wierman ME, Yuen KCJ, Zatelli MC, Melmed S. Multidisciplinary management of acromegaly: A consensus. Reviews in endocrine & metabolic disorders. 2020 Dec:21(4):667-678. doi: 10.1007/s11154-020-09588-z. Epub 2020 Sep 10
[PubMed PMID: 32914330]
Level 3 (low-level) evidence
[22]
Chaudhary V, Bano S. Imaging of pediatric pituitary endocrinopathies. Indian journal of endocrinology and metabolism. 2012 Sep:16(5):682-91. doi: 10.4103/2230-8210.100635. Epub
[PubMed PMID: 23087850]
[23]
Leonart LP, Ferreira VL, Tonin FS, Fernandez-Llimos F, Pontarolo R. Medical Treatments for Acromegaly: A Systematic Review and Network Meta-Analysis. Value in health : the journal of the International Society for Pharmacoeconomics and Outcomes Research. 2018 Jul:21(7):874-880. doi: 10.1016/j.jval.2017.12.014. Epub 2018 Feb 8
[PubMed PMID: 30005760]
Level 1 (high-level) evidence
[24]
Albani A, Perez-Rivas LG, Reincke M, Theodoropoulou M. PATHOGENESIS OF CUSHING DISEASE: AN UPDATE ON THE GENETICS OF CORTICOTROPINOMAS. Endocrine practice : official journal of the American College of Endocrinology and the American Association of Clinical Endocrinologists. 2018 Oct 2:24(10):907-914. doi: 10.4158/EP-2018-0111. Epub 2018 Aug 7
[PubMed PMID: 30084690]
[25]
Hirsch D, Shimon I, Manisterski Y, Aviran-Barak N, Amitai O, Nadler V, Alboim S, Kopel V, Tsvetov G. Cushing's syndrome: comparison between Cushing's disease and adrenal Cushing's. Endocrine. 2018 Dec:62(3):712-720. doi: 10.1007/s12020-018-1709-y. Epub 2018 Aug 6
[PubMed PMID: 30084101]
[26]
Loriaux DL. Diagnosis and Differential Diagnosis of Cushing's Syndrome. The New England journal of medicine. 2017 Jul 13:377(2):e3. doi: 10.1056/NEJMc1705984. Epub
[PubMed PMID: 28700850]
[27]
Fleseriu M, Biller BMK, Freda PU, Gadelha MR, Giustina A, Katznelson L, Molitch ME, Samson SL, Strasburger CJ, van der Lely AJ, Melmed S. A Pituitary Society update to acromegaly management guidelines. Pituitary. 2021 Feb:24(1):1-13. doi: 10.1007/s11102-020-01091-7. Epub 2020 Oct 20
[PubMed PMID: 33079318]
[28]
Fleseriu M, Auchus R, Bancos I, Ben-Shlomo A, Bertherat J, Biermasz NR, Boguszewski CL, Bronstein MD, Buchfelder M, Carmichael JD, Casanueva FF, Castinetti F, Chanson P, Findling J, Gadelha M, Geer EB, Giustina A, Grossman A, Gurnell M, Ho K, Ioachimescu AG, Kaiser UB, Karavitaki N, Katznelson L, Kelly DF, Lacroix A, McCormack A, Melmed S, Molitch M, Mortini P, Newell-Price J, Nieman L, Pereira AM, Petersenn S, Pivonello R, Raff H, Reincke M, Salvatori R, Scaroni C, Shimon I, Stratakis CA, Swearingen B, Tabarin A, Takahashi Y, Theodoropoulou M, Tsagarakis S, Valassi E, Varlamov EV, Vila G, Wass J, Webb SM, Zatelli MC, Biller BMK. Consensus on diagnosis and management of Cushing's disease: a guideline update. The lancet. Diabetes & endocrinology. 2021 Dec:9(12):847-875. doi: 10.1016/S2213-8587(21)00235-7. Epub 2021 Oct 20
[PubMed PMID: 34687601]
Level 3 (low-level) evidence
[29]
Nieman LK, Biller BM, Findling JW, Murad MH, Newell-Price J, Savage MO, Tabarin A, Endocrine Society. Treatment of Cushing's Syndrome: An Endocrine Society Clinical Practice Guideline. The Journal of clinical endocrinology and metabolism. 2015 Aug:100(8):2807-31. doi: 10.1210/jc.2015-1818. Epub 2015 Jul 29
[PubMed PMID: 26222757]
Level 1 (high-level) evidence
[30]
Azzalin A, Appin CL, Schniederjan MJ, Constantin T, Ritchie JC, Veledar E, Oyesiku NM, Ioachimescu AG. Comprehensive evaluation of thyrotropinomas: single-center 20-year experience. Pituitary. 2016 Apr:19(2):183-93. doi: 10.1007/s11102-015-0697-7. Epub
[PubMed PMID: 26689573]
[31]
van der Lely AJ, Biller BM, Brue T, Buchfelder M, Ghigo E, Gomez R, Hey-Hadavi J, Lundgren F, Rajicic N, Strasburger CJ, Webb SM, Koltowska-Häggström M. Long-term safety of pegvisomant in patients with acromegaly: comprehensive review of 1288 subjects in ACROSTUDY. The Journal of clinical endocrinology and metabolism. 2012 May:97(5):1589-97. doi: 10.1210/jc.2011-2508. Epub 2012 Feb 22
[PubMed PMID: 22362824]
[32]
Devoe DJ, Miller WL, Conte FA, Kaplan SL, Grumbach MM, Rosenthal SM, Wilson CB, Gitelman SE. Long-term outcome in children and adolescents after transsphenoidal surgery for Cushing's disease. The Journal of clinical endocrinology and metabolism. 1997 Oct:82(10):3196-202
[PubMed PMID: 9329338]
[33]
Ayuk J, Clayton RN, Holder G, Sheppard MC, Stewart PM, Bates AS. Growth hormone and pituitary radiotherapy, but not serum insulin-like growth factor-I concentrations, predict excess mortality in patients with acromegaly. The Journal of clinical endocrinology and metabolism. 2004 Apr:89(4):1613-7
[PubMed PMID: 15070920]
[34]
Broersen LHA, Zamanipoor Najafabadi AH, Pereira AM, Dekkers OM, van Furth WR, Biermasz NR. Improvement in Symptoms and Health-Related Quality of Life in Acromegaly Patients: A Systematic Review and Meta-Analysis. The Journal of clinical endocrinology and metabolism. 2021 Jan 23:106(2):577-587. doi: 10.1210/clinem/dgaa868. Epub
[PubMed PMID: 33245343]
Level 1 (high-level) evidence
[35]
Cuevas-Ramos D, Carmichael JD, Cooper O, Bonert VS, Gertych A, Mamelak AN, Melmed S. A structural and functional acromegaly classification. The Journal of clinical endocrinology and metabolism. 2015 Jan:100(1):122-31. doi: 10.1210/jc.2014-2468. Epub
[PubMed PMID: 25250634]
[36]
Coulden A, Hamblin R, Wass J, Karavitaki N. Cardiovascular health and mortality in Cushing's disease. Pituitary. 2022 Oct:25(5):750-753. doi: 10.1007/s11102-022-01258-4. Epub 2022 Jul 22
[PubMed PMID: 35869339]